Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036690 (
sepsis
)
59,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Programmed cell death 1
(
PD-1
) plays an important pathologic role in
sepsis
-induced immunosuppression. However, whether
PD-1
overexpression occurs early during septic shock is unknown and its regulation mechanism is also unknown. Our study investigated the expressions of
PD-1
/programmed death-ligand 1 (PD-L1) on immune cells in peripheral blood from the early-stage septic shock patients. We found that both
PD-1
and PD-L1 showed increased expressions on the CD4(+) T cells and monocytes. It indicated that
PD-1
expression might be an early biomarker to assess illness severity and predict the prognosis of septic shock. Then, we further investigated the mechanism underlying the regulation of
PD-1
expression. Our data showed that Notch signaling pathway was activated in both septic shock patients and lipopolysaccharide- (LPS-) tolerant THP1 cells and both interleukin-10 (IL-10) and
PD-1
were increased in the THP1 cells. Inhibition of Notch signaling by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenyl glycinet-butyl ester (DAPT) induced significantly decreased expressions of
PD-1
and IL-10 in the LPS-tolerant cell model. Our work suggested that Notch signaling pathway was involved in the regulation of
PD-1
expression.
...
PMID:Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression. 2606 74
Recent efforts have focused on immunoadjuvant therapies for
sepsis
. The host inflammatory response consequent to initial exposure to pathogens is often followed by anti-inflammatory forces, resulting in increased morbidity and mortality in such critically ill patients. In the subacute stage of
sepsis
, apoptosis (type I programmed cell death) and subsequently autophagy (type II programmed cell death) have been attracting recent research interest. Although many patients may die during the initial cytokine storm, those who survive this phase might acquire defining characteristics of profound immunosuppression, including failure to clear the primary infection, development of secondary opportunistic infections, and reactivation of latent viruses. Both types of cell death are currently thought to be associated with this subacute immunosuppressive phase of
sepsis
, and acceleration of autophagy might alleviate immunosuppression through regulation of apoptosis of key immune effector cells.
Programmed cell death 1
(
PD-1
) and its corresponding ligand play a major pathological role in immunosuppression not only in cancer but also in
sepsis
. Positive costimulatory pathways in T cells, such as CD28 signaling, permit the effector T cell to expand, persist, and effectively clear antigen. However,
PD-1
is a negative costimulatory pathway on T cells that broadly enhances immunosuppressive signals across the innate and adaptive immune system. To counter this immunosuppression in
sepsis
, checkpoint blockade has garnered attention in an area of clinical research. In this review, we introduce some approaches of immunotherapy using anti-
PD-1
antibody in infectious diseases and share our future perspectives.
...
PMID:Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike. 3033 75